CytoMed Therapeutics Limited Ordinary Shares (GDTC) is a publicly traded Healthcare sector company. As of September 30, 2026, GDTC trades at $0.94 with a market cap of $11.30M and a P/E ratio of 0.00. GDTC moved +0.00% today. Year to date, GDTC is -37.58%; over the trailing twelve months it is -50.52%. Its 52-week range spans $0.68 to $3.68. Analyst consensus is buy with an average price target of $4.16. Rallies surfaces GDTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CytoMed Therapeutics Limited Ordinary Shares (GDTC) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GDTC moved +0.00% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $0.94 |
| Market Cap | $11.30M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.68 |
| 52-Week Low | $0.68 |
| Volume | 6.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover GDTC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.16.